BACKGROUND INFORMATION ON THE PROCEDURE 
1. 
Submission of the dossier 
The  applicant  Aventis  Pasteur  MSD  submitted  on  1  August  2000  an  application  for  a  Marketing 
Authorisation  to  the  European  Agency  for  the  Evaluation  of  Medicinal  Products  (EMEA)  for 
HBVAXPRO, in accordance with the centralised procedure falling within the scope of Part A of the 
Annex to Council Regulation No (EEC) 2309/93 of 22 July 1993. 
The Rapporteur and Co-Rapporteur appointed by the CPMP were: 
Rapporteur:  Dr. M. Haase 
Co-Rapporteur:  Dr. D. Brasseur 
Licensing status: 
HBVAXPRO  has  been  given  a  Marketing  Authorisation  in  the  United  States  of  America  on  
27 August 1999, Australia on 14 December 1999 and New Zealand on 16 December 1999 
2. 
• 
• 
• 
• 
• 
• 
• 
Steps taken for the assessment of the product 
In its June meeting the CPMP agreed on an accelerated review for this application responding to 
the apparent urgent need to provide thiomersal-free hepatitis B vaccine mainly to the European 
paediatric population. 
The procedure started on 31 October 2000. 
The  Rapporteur's  first  Assessment  Report  was  circulated  to  all  CPMP  members  on  20 
November 2000 (Annex 1). The Co-Rapporteur's first Assessment Report was circulated to all 
CPMP members on 20 November 2000 for Part III and IV and 29 November for Part II  (Annex 
2). 
During  the  meeting  on  12-14  December  2000  the  CPMP  agreed  on  the  consolidated  List  of 
Questions to be sent to the applicant. The final consolidated List of Questions was sent to the 
company on 14 December 2000 (Annex 3). 
The  applicant  submitted  the  responses  to  the  CPMP  consolidated  List  of  Questions  on  21 
December 2000 
The Rapporteur circulated the response Assessment Report on the company’s responses to the 
List of Questions to all CPMP members on 8 January 2001 (Annex 5) 
During the meeting on 23-25 January 2001 the CPMP, in the light of the overall data submitted 
and  the  scientific  discussion  within  the  Committee,  issued  a  positive  opinion  for  granting  a 
Marketing Authorisation to HBVAXPRO on 25 January 2001. 
1/1 
EMEA 2005 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
